Acetylon Pharma spins out non cancer indications of ricolinostat to Regenacy Pharma and Celgene will acquire Acetylon Pharma and with it citarinostat (ACY-241) and ricolinostat (ACY-1215)

Acetylon Pharmaceuticals announced that it has entered into an agreement to be acquired by Celgene Corporation. Prior to the consummation of the acquisition, Acetylon will spin out a new company, Regenacy Pharmaceuticals, LLC, which will focus on the development of novel drug candidates that selectively regenerate intracellular transport and upregulate gene expression to modify the course of disease. Regenacy will receive exclusive worldwide rights to Acetylon�s Phase II selective histone deacetylase 6 (HDAC6) inhibitor, ricolinostat (ACY-1215), for the treatment of certain non-cancer disease indications including neuropathies, as well as Acetylon�s preclinical selective HDAC1,2 inhibitor candidates and patent families for development in all human disease indications including sickle cell disease and beta-thalassemia.The acquisition will provide Celgene with, among other things, worldwide rights to Acetylon�s selective HDAC6 inhibitor programs and intellectual property in oncology, neurodegeneration, and autoimmune disease, including its lead drug candidates citarinostat (ACY-241) and ricolinostat (ACY-1215). Financial terms of the acquisition are not being disclosed